ALTURiX acquires UK rights to liothyronine

30 May 2022

ALTURiX - a rapidly-growing British pharmaceutical company - has acquired the exclusive rights to liothyronine for the UK following the finalization of an agreement with HELM AG, based in Hamburg, Germany.

Founded in 2020 following the acquisition of two family-owned pharmaceutical companies, ALTURiX has a portfolio of well-known medicines which are prescribed widely by the National Health Service (NHS). The mission set out by the ALTURiX founders is to reliably provide branded products at an appropriate price. ALTURiX was created and shaped to provide these high-quality medicines to the NHS with streamlined efficiency.

The company’s portfolio includes three heritage branded products acquired from Novartis (NOVN: VX), all proven and acknowledged to improve patients’ health. ALTURiX reliably supplies these products to the NHS and other international markets, using its manufacturing partner based in Switzerland. This is in keeping with the company’s commitment to reliably deliver high-quality products, at a sensible price.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK